The Investigator develops an idea for using VNS Therapy in either a new way (e.g., treating co-morbidities associated with epilepsy and/or treatment resistant depression), or in a new patient population (e.g. a patient population that might uniquely benefit from VNS Therapy, but within FDA approved labeling).

Often, much of the Clinical Research Committee time is spent tracking down relevant information before a thorough review of the study can occur.  Providing the criteria outlined on this website should expedite the review process and, accordingly, our decision on supporting your project.

Next Step: Submit Letter of Intent

Back to: Submission Process Flowchart